|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: -2.43%|
|Previous Close: $478.46|
|52 Week Range: $455.18 - $585.67|
|Oustanding Shares: 40,161,022|
|Market Cap: 19,215,442,586|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||12||11||11||12|
|Growth Rate (Year over Year)||15.16%||-4.87%||12.27%||15.98%|
It was good to see, if only briefly.
There are plenty of solid earnings trades to choose from over the next day or so.
Don't try to grab a trade ahead of earnings.
The momentum favorite gets slammed on news of an FDA investigation.
ISRG was upgraded from Hold to Buy, Cantor Fitzgerald said. $575 price target. Stock has overreactd to news of the FDA probe.
ISRG was upgraded to Buy, Goldman Sachs said. $715 price target. Fundamentals appear to be improving.
There continues to be solid sector rotation, and you have to obey the price action above all else.
Shares of ISRG now seen reaching $625, according to Lazard Capital Markets. Estimates also increased, as the company is seeing higher growth across the board. Buy rating.
Sometimes you can catch them using price targets to hedge their ratings.
Contributor Ken Shreve takes a look at upcoming data and some key earnings reports in a shortened week of trading.